Evolva is a publicly traded, biotech company based in Reinach, Switzerland. It focuses on discovering, producing, and supplying sustainable ingredients, in particular, for health, wellness, and nutrition.
Using synthetic biology, Evolva takes baker's yeast and gives it the ability to make the same ingredient that would normally be made by a plant or animal. The company's lead products are stevia sweeteners, nootkatone, and resveratol. It has five key products, which are:
- EverSweet Stevia
NootkaShield is a product that combines Evolva's yeast fermentation process with a properietary conversion technique to product. It's main ingredient is Nootkatone, which is known to effectively repel and control a range of insect pests, including ticks, mosquitos, and other nuisance insects. NootkaShield is aimed to be used for pest control at a commercial scale and is available for research, product development, testing, and potential registration.
Resveratol is a polyphenol that is found in several types of plants and has shown evidence of working at a cellular level to assist healthy aging. Evolva produces resveratol under the name Veri-te, which can be formulated into multiple applications, including capsules, tablets, softgels, liquid shots, beverages, powder sticks, film strips, chocolate, chewing gum, creams, serum, and cosmetics.
Evolva also has some products approved flavor and fragrance applications. Normally extracted from the skin of grapefruits, Evolva's nootkatone (EveNootkatone) flavor and fragrance is instead brewed from sugar. Another flavor and fragrance the company produces is EveValencene, a citrus aroma (valencene) that is characteristic in the smell of oranges. This too is brewed from sugar.
EverSweet is a calorie-free sweetener that is made using Evolva's yeast fermentation process. It was launched in 2018 in partnership with Cargill. The latter is also the company that manufactures EverSweet.
Senior VP, NootkaShield
VP, Regulatory Affairs
Melya Hughes Crameri
VP, Sales and Marketing
Philippe Prochasson, Ph.D.
Evolva to axe almost half its workforce in restructuring overhaul
EVOLVA: an Interview with CEO Neil Goldsmith | PLOS Synthetic Biology Community